Π‘ΠΊΡΡΡΠ°Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ Π²ΠΈΡΡΡΠΎΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π Π² ΡΡΡΡΠΊΡΡΡΠ΅ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π²ΠΈΡΡΡΠΎΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘
ΠΠΈΡΡΠ΅ΡΡΠ°ΡΠΈΡ
ΠΠ°ΠΆΠ½ΠΎ ΠΎΡΠΌΠ΅ΡΠΈΡΡ, ΡΡΠΎ ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ, Ρ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ°ΡΡΠΈ Π»ΠΈΡ, ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ Π²ΠΈΡΡΡΠΎΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π‘, Π² ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ HBsAg, Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΡΡΡΡ Π°Π½ΡΠΈΡΠ΅Π»Π° ΠΊ Π²ΠΈΡΡΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π. Π’Π°ΠΊΠ°Ρ ΡΠΎΡΠΌΠ° ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π²ΠΈΡΡΡΠΎΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π (HBV), Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠ°ΡΡΡ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ HBsAg, ΠΏΡΠΈΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ Π°Π½ΡΠΈΡΠ΅Π» ΠΊ Π²ΠΈΡΡΡΠ½ΡΠΌ Π°Π½ΡΠΈΠ³Π΅Π½Π°ΠΌ (Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, anti-HBcor IgG) ΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ HBV DNA Π² ΡΠΊΠ°Π½ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- ΠΠ±Π΄ΡΡΠ°Ρ ΠΌΠ°Π½ΠΎΠ² Π.Π’. ΠΠ°ΡΠ΅Π½ΡΠ½Π°Ρ HBV-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΏΠ΅ΡΠ΅Π½ΠΈ // Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π» Π³Π°ΡΡΡΠΎΡΠ½ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, Π³Π΅ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΊΠΎΠ»ΠΎΠΏΡΠΎΠΊΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. 2002. — № 6. — Π‘. 31 — 37.
- ΠΠ½Π΄ΡΠ΅ΠΉΡΠ΅Π²Π° Π.Π. ΠΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΎΡΡΠΎΡΠΎΠΏΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΏΡΠΈ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΡΠΌΠΈ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΡΠΌΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ // Consilium Medicum. 2004. — Π’.6. — № 6. — Π‘. 25 — 27.
- ΠΠΏΡΠΎΡΠΈΠ½Π° Π. Π. Π‘Π΅ΡΠΎΠ² Π.Π. ΠΠ°ΡΠΎΠ³Π΅Π½Π΅Π· Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π // ΠΡΡ ΠΈΠ² ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. — 2001. № 2. — Π‘. 58—62.
- ΠΠ°Π»ΠΈΠΌΠΎΠ²Π° Π‘. Π€. ΠΠ°Π΅Π²ΡΠΊΠ°Ρ Π.Π. ΠΠ²Π°ΡΠΊΠΈΠ½ Π. Π’. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΠΏΠΎΠ΄Ρ ΠΎΠ΄Ρ ΠΊ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠΌ Π // Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π» Π³Π°ΡΡΡΠΎΡΠ½ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, Π³Π΅ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΊΠΎΠ»ΠΎΠΏΡΠΎΠΊΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. 2009. — № 3. — Π‘. 14 -16.
- ΠΠ°Π½ΠΈΠ½Π° Π. Π. ΠΡΡΠ΅Π³ΡΠ½ Π.Π. ΠΡΠ°Π΅Π²Π° Π. Π. ΠΠΌΠΈΡΡΠΈΠ΅Π² Π.Π. ΠΠΎΡΡΡΡΠ½Π½ΠΈΠΊ Π. Π. ΠΠΈΡ Π°ΠΉΠ»ΠΎΠ² Π.Π. Π§Π°ΡΡΠΎΡΠ° Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΡΠΊΡΡΡΠΎΠΉ ΠΠΠ-ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΡΡΠ΅Π΄ΠΈ Π΄ΠΎΠ½ΠΎΡΠΎΠ² ΠΊΡΠΎΠ²ΠΈ ΠΈ Π² Π³ΡΡΠΏΠΏΠ°Ρ ΡΠΈΡΠΊΠ° ΠΈΠ½ΡΠΈΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΠΠ // ΠΠΈΡ Π²ΠΈΡΡΡΠ½ΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠ². 2007. — № 4. — Π‘. 8.
- ΠΠ²Π°ΡΠΊΠΈΠ½ Π.Π’. ΠΠΎΠ»Π΅Π·Π½ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΈ ΠΆΠ΅Π»ΡΠ΅Π²ΡΠ²ΠΎΠ΄ΡΡΠΈΡ ΠΏΡΡΠ΅ΠΉ- Π ΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ Π΄Π»Ρ Π²ΡΠ°ΡΠ΅ΠΉ 2-Π΅ ΠΈΠ·Π΄.- Π.: Π-ΠΠ΅ΡΡΠΈ, 2005 — Π‘. 123, 125, 230.
- ΠΠ²Π°ΡΠΊΠΈΠ½ Π.Π’. ΠΠΌΠΌΡΠ½Π½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° ΠΈ ΠΏΠΎΠ²ΡΠ΅ΠΆΠ΄Π΅Π½ΠΈΡ ΠΏΠ΅ΡΠ΅Π½ΠΈ ΠΏΡΠΈ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠ°Ρ Π ΠΈ Π‘ // Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π» Π³Π°ΡΡΡΠΎΡΠ½ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, Π³Π΅ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΊΠΎΠ»ΠΎΠΏΡΠΎΠΊΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. 2009. — № 5. — Π‘. 3 — 9.
- ΠΠ²Π°ΡΠΊΠΈΠ½ Π. Π’. ΠΠ΅ΡΠΌΠ°Π½ Π.Π. ΠΠ°Π΅Π²ΡΠΊΠ°Ρ Π. Π. Π‘ΠΊΡΡΡΠ°Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΡ Π²ΠΈΡΡΡΠΎΠΌ Π³Π΅ΠΏΠ°ΡΠΈΡΠ° Π // Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π» Π³Π°ΡΡΡΠΎΡΠ½ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, Π³Π΅ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΊΠΎΠ»ΠΎΠΏΡΠΎΠΊΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. 2008. — № 2. — Π‘. 4 — 7.
- ΠΠ²Π°ΡΠΊΠΈΠ½ Π. Π’. ΠΠΎΡΠΎΠ·ΠΎΠ²Π° Π.Π. ΠΠ°Π΅Π²ΡΠΊΠ°Ρ Π. Π. Π‘ΠΎΠΊΠΎΠ»ΠΈΠ½Π° Π.Π. ΠΠ΅ΡΠΌΠ°Π½ Π. Π. ΠΡΠ½Π΄ΠΈΠ½Π° Π.Π. Π€Π°ΠΊΡΠΎΡΡ ΡΠΈΡΠΊΠ° ΡΠ°Π·Π²ΠΈΡΠΈΡ Π³Π΅ΠΏΠ°ΡΠΎΡΠ΅Π»Π»ΡΠ»ΡΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ // Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π» Π³Π°ΡΡΡΠΎΡΠ½ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, Π³Π΅ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΊΠΎΠ»ΠΎΠΏΡΠΎΠΊΡΠΎΠ»ΠΎΠ³ΠΈΠΈ. -2009. -№ 1.- Π‘. 4- 16.
- ΠΠ²Π°ΡΠΊΠΈΠ½ Π. Π’. ΠΠ°Π²Π»ΠΎΠ² Π§.Π‘. ΠΠΏΡΡ ΠΎΠ»ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ, ΠΏΡΠ΅Π΄ΡΠ°ΠΊΠΎΠ²ΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ. ΠΠ΅ΠΏΠ°ΡΠΎΡΠ΅Π»Π»ΡΠ»ΡΡΠ½Π°Ρ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ° // Π Π°ΡΠΈΠΎΠ½Π°Π»ΡΠ½Π°Ρ ΡΠ°ΡΠΌΠ°ΠΊΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΎΡΠ³Π°Π½ΠΎΠ² ΠΏΠΈΡΠ΅Π²Π°ΡΠ΅Π½ΠΈΡ. Π.: ΠΠΈΡΡΠ΅ΡΡΠ°, 2003. -Π‘. 459−464.
- ΠΠ°Π΅Π²ΡΠΊΠ°Ρ Π.Π. ΠΠ΅ΠΏΠ°ΡΠΈΡ Π ΠΈ ΡΠ΅ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠ²Π½ΠΎΠ΅ Π·Π΄ΠΎΡΠΎΠ²ΡΠ΅ // Π ΠΎΡΡΠΈΠΉΡΠΊΠΈΠΉ ΠΆΡΡΠ½Π°Π» Π³Π°ΡΡΡΠΎΡΠ½ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, Π³Π΅ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΊΠΎΠ»ΠΎΠΏΡΠΎΠΊΡΠΎΠ»ΠΎΠ³ΠΈΠΈ — 2009. № 5.- Π‘. 4 9.
- ΠΠ°Π΅Π²ΡΠΊΠ°Ρ Π.Π. ΠΠ΅ΡΠ΅Π½ΠΈΠ΅ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ Π²ΠΈΡΡΡΠ½ΡΡ Π³Π΅ΠΏΠ°ΡΠΈΡΠΎΠ² // ΠΠ΅ΡΠ°ΡΠΈΠΉ Π²ΡΠ°Ρ- 2005. -№ 2.-Π‘. 54−58.
- ΠΠΈΡ Π°ΠΉΠ»ΠΎΠ² Π.Π. ΠΠ½Π°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΠΏΡΠ°Π²ΠΊΠ° «ΠΠ°ΡΠ΅Π½ΡΠ½ΡΠ΅ Π³Π΅ΠΏΠ°ΡΠΈΡΡ Π ΠΈ Π‘». -Π.: 2008.-Π‘. 2−5.
- ΠΠ°Π·Π°ΡΠ΅Π½ΠΊΠΎ Π‘.Π. ΠΠ²ΠΎΠ»ΡΡΠΈΠΎΠ½Π½Π°Ρ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ // ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ II ΠΠ΅ΠΆΠ΄ΡΠ½Π°ΡΠΎΠ΄Π½ΠΎΠΉ ΠΊΠΎΠ½ΡΠ΅ΡΠ΅Π½ΡΠΈΠΈ «ΠΡΠΎΠ±Π»Π΅ΠΌΠ° Π²ΠΈΠ΄Π° ΠΈ Π²ΠΈΠ΄ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠ΅». Π’ΠΎΠΌΡΠΊ: Π’ΠΎΠΌΡΠΊΠΈΠΉ Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΡΠΉ ΡΠ½ΠΈΠ²Π΅ΡΡΠΈΡΠ΅Ρ. 2002 Π’.2. — Π‘. 82 — 93.
- ΠΠΎΠ΄ΡΠΌΠΎΠ²Π° Π‘.Π. ΠΠΎΠ»Π΅Π·Π½ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ- Π ΡΠΊΠΎΠ²ΠΎΠ΄ΡΡΠ²ΠΎ Π΄Π»Ρ Π²ΡΠ°ΡΠ΅ΠΉ. 4-Π΅ ΠΈΠ·Π΄Π°Π½ΠΈΠ΅, ΠΏΠ΅ΡΠ΅ΡΠ°Π±ΠΎΡΠ°Π½Π½ΠΎΠ΅ ΠΈ Π΄ΠΎΠΏΠΎΠ»Π½Π΅Π½Π½ΠΎΠ΅. — Π.: ΠΠ΅Π΄ΠΈΡΠΈΠ½Π°, 2005. — Π‘. 23.
- Π₯ΡΠ±ΡΡΠΈΡ Π. Π¨. ΠΠ½Π΄ΡΠ΅ΠΉΡΠ΅Π²Π° Π.Π. ΠΡΡΠ°Π²Π΅Π»Ρ Π‘. Π. ΠΡΠ»ΡΠ΅Π² Π.Π. Π‘Π°Π»ΠΈΠ΅Π½ΠΊΠΎ Π. Π. Π§ΠΆΠ°ΠΎ Π.Π. ΠΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π²Π΅Π΄Π΅Π½ΠΈΡ «ΠΠΈΡΡΠ° ΠΎΠΆΠΈΠ΄Π°Π½ΠΈΡ"ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠ°ΡΠΈΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΈ // Π’ΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΎΠ»ΠΎΠ³ΠΈΡ. 2009. — № 1. — Π‘. 13.
- Alter H.J. Π’ΠΎ Π‘ or Not Π’ΠΎ Π‘: These are the Questions // Blood. 1995- 85 (7): 1681−1695
- Altfeld M. Rockstroh J.K. Addo M. Kupfer B. Pult I. Will H. Reactivation of hepatitis Π in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal // J Hepatol 1998- 29: 306−309
- American College of Obstetricians and Gynecologists. Viral hepatitis in pregnancy// Practice bulletin 2007- 86: 15.
- Blackberg J. Kidd-Ljunggren K. Occult hepatitis Π virus after acute self-limited infection persisting for 30 years without sequence variation // J Hepatol. 2000- 33:992−997.
- Blum H. Galun E. Liang T.J. von Weizsacker F. Wands J.R. Naturally occurring missense mutation in the polymerase gene terminating hepatitis Π virus replication // J Virol. 1991- 65:1836−1842.
- Bock C.T. Schwinn S. Locarnini S. Fyfe J. Manns M.P. Trautwein C. Structural organization of the hepatitis Π virus minichromosome // J Mol Biol. 2001- 307:183−196.
- Boonstra A. Andrea M. Woltman. Harry L.A. Janssen. Immunology of hepatitis Π and hepatitis Π‘ virus infections // Clinical Gastroenterology Best Practice and research. 2008- 22 (6): 1049−1061.
- Brechot C. Hadchouel M. Scotto J. Fonck M. Potet F. et al. State of hepatitis Π virus DNA in hepatocytes of patients with hepatitis Π surface antigen-positive and -negative liver diseases // Proc Nat Acad Sci USA. 1981- 78: 3906−3910.
- Brechot Π‘. Pathogenesis of hepatitis Π virus-related hepatocelular carcinoma: old and new paradigms // Gastroenterology. 2004- 127: 556−561.
- Brechot C. Thiers V. Kremsdorf D. Nalpas B. Paterlini-Brechot P. Persistent hepatitis Π virus infection in subjects without hepatitis Π surface antigen: clinically significant or purely «occult»? // Hepatology (Baltimore MD). 2001- 34: 194−203.
- Cacciola I. Pollicino T. Squadrito G. Cerenzia G. Orlando ME. Raimondo G. Occult hepatitis Π vims infection in patients with chronic hepatitis Π‘ liver disease // N Engl J Med. 1999- 341: 22−26.
- Carman WF. van Deursen FJ. Mimms LT. Hardie D. Coppola R. Decker R. et al. The prevalence of surface antigen variants of hepatitis Π virus in Papua New guinea, South Africa and Sardinia // Hepatology (Baltimore, MD). 1997- 26: 1658−1666.
- Chaudhuri V. Tayal R. Nayak B. Acharya SK. Panda SK. Occult hepatitis Π virus infection in chronic liver disease full-length genome and analysis of mutant surface promoter// Gastroenterology. 2004- 127: 1356−1371.
- Chazouilleres O. Mamish D. Kim M. Carey K. Ferrell L. Roberts JP. et al. Occult hepatitis Π virus as source of infection in liver transplant recipients // Lancet. 1994−343:142−146.
- Chemin I. Trepo C. Clinical impact of occult HBV infections // J Clin Virol. -2005- 34: 515−521.
- Chen SY. Kao CF. Chen CM. Shih CM. Hsu MJ. Chao CH. et al. Mechanisms for inhibition of hepatitis Π virus gene expression and replication by hepatitis Π‘ virus core protein // J Biol Chem. 2003- 278: 591−607.
- Cheng AL. Hsiung CA. Su I J. et al. Steroid-free chemotherapy decreasesrisk of hepatitis Π virus (HBV) reactivation in HBV-carriers with lymphoma // Hepatology. 2003- 37(6): 1320−1328.
- Chi-Jen Chu. Shou-Dong Lee. Hepatitis Π Virus/Hepatitis Π‘ Virus Coinfection: Epidemiology, Clinical Features, Viral Interactions and Treatment// J Gastroenterol Hepatol. 2008- 23(4): 512−520.
- Conjeevaram HS. Lok AS. Occult hepatitis Π virus infection: a hidden menace? // Hepatology (Baltimore MD). 2001- 34: 204−206.
- Degos F. Lugassy C. Degot C. Debure A. Carnot F. Thiers V. Hepatitis Π virus and hepatitis Π related viral infection in renal transplant recipients // Gastroenterology. 1988- 94: 151−156.
- De Feo TM. Poli F. Mozzi F. Moretti MP. Scalamogna M. Risk of transmission of hepatitis Π virus from anti-HBC positive cadaveric organ donors: a collaborative study // Transpl Proc. 2005- 37: 1238−1239.
- Dervite I. Hober D. Morel P. Acute hepatitis Π in a patient with antibodies to hepatitis Π surface antigen who was receiving rituximab // N Engl J Med. -2001−344:68−69.
- Dickson RC. Everhart JE. Lake JR. Wei Y. Seaberg EC. Wiesner RH. et al. Transmission of hepatitis Π by transplantation of livers from donors positive for antibody to hepatitis Π core antigen // Gastroenterology. 1997- 113: 16 681 674.
- Dite P. D. Labrecque. et al. World Gastroenterology Organisation practice guideline: Esophageal varices. 2008.
- Donato F. Gelatti U. Limina R. Fattovich G. Souther Europe as an example of interaction between various enviror mental factors: a systematic review of the epidemiologic evi dence // Oncogene. 2006- 25: 3756−3770.
- Duclos-Vallee J. Roche B. Samuel D. Liver transplantation in patients with hepatitis Π virus, hepatitis Π‘ virus, or human immunodeficiency virus // Presse Med.-2009- 38(9): 1281−1289.
- EASL Clinical Practice Guidelines: Management of chronic hepatitis Π // J Hepatol. 2009- 50: 2−16.
- El-Serag HB. Hepatocellular carcinoma: recent trends in the United States // Gastroenterology.- 2004- 127(5 Suppl 1): 527−534.
- Everson G.T. Trotter J.F. Kugelmas M. Long term outcome of patients with chronic hepatitis Π‘ and decompensated liver disease treated with the LADR protocol (low accelerating dose regimen) // Hepatology. 2002, p.36.
- Fujiwara K- Yasuhito Tanaka- Etsuro Orito et al. Association Between Occult Hepatitis Π Virus DNA Viral Load and Aminotransferase Levels in Patients With Hepatitis Π‘ Virus-Related Chronic Liver Disease // Gastroenterol Hepatol. -2004- 19(12).
- Fukuda R. Ishimura M. Kushiyama Y. Moriyama M. Ishihara S. Chowdhury A. et al. Hepatitis Π virus with X gene mutations is associated with the majority of serologically «silent» non-b non-c chronic hepatitis // Microbiol Immunol. -1996- 40: 481−488.
- Ganem D. Prince AM. Hepatitis Π virus infection natural history and clinical consequences // N Engl J Med. — 2004- 350: 1118−1129.
- Grumayer ER. Panzer S. Ferenci P. Gadner H. Recurrence of hepatitis Π in children with serologic evidence of past hepatitis Π virus infection undergoing antileukemic chemiotherapy // J Hepatol. 1989- 8: 232−235
- Guidotti LG. Chisari FV. Noncytolytic control of viral infections by the innateand adaptive immune response // Annu Rev Immunol. 2001- 19: 65−91.
- Guidotti LG. Rochford R. Chung J. Shapiro M. Purcell R. Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection// Science. 1999- 284: 825−829.
- Hass M. Hannoun C. Kalinina T. Sommer G. Manegold C. Gunther S. Functional analysis of hepatitis Π virus reactivating in hepatitis Π surface antigen-negative individuals // Hepatology (Baltimore, MD). 2005- 42: 93 103.
- Hoofhagle JH. Dusheiko GM. Schafer DF. Jones EA. Micetich KC. et al. Reactivation of chronic hepatitis Π virus infection by cancer chemiotherapy// Ann Intern Med. 1982- 96: 447−449.
- Hoofhagle JH. Seeff LD. Bales ZB. Zimmerman HJ. Type Π hepatitis after transfusion with blood containing antibody to hepatitis Π core antigen // N Engl J Med. 1978- 298: 1379−1383.
- Hou J. Karayiannis P. Walters J. Luo K. Liang C. Thomas H. A unique insertion in the S gene of surface antigen-negative hepatitis Π virus Chinese carriers // Hepatology (Baltimore, MD). 1995- 21: 273−278
- Hou J. Wang Z. Cheng J. Lin Y. Lau GK. Sun J. et al. Prevalence of naturally occurring surface gene variants of hepatitis Π virus in nonimmunized surface antigen-negative Chinese carriers // Hepatology (Baltimore, MD). 2001- 34: 1027−1034.
- Hsu C. Hsiung CA. Su IJ. et al. A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis Π reactivation in non-Hodgkin's lymphoma: a randomized trial // Hepatology. 2008- 47(3): 844−853.
- Hu KQ. Occult hepatitis Π vims infection and its clinical implications // J Viral Hepat. 2002- 9: 243−257.
- Huo TI. Wu JC. Lee PC. Chau GY. Lui WY. Tsay SH. et al. Sero-clearance of hepatitis Π surface antigen in chronic carriers does not necessarily imply a good prognosis // Hepatology (Baltimore, MD). 1998- 28: 231−236.
- Hussain M. Soldevila-Pico Π‘. Emre S. Luketic V. Lok AS. NIH HBV-OLT Study Group. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation // Liver Transpl. -2007- 13(8): 1137−1144.
- Iannitto E. Minardi V. Calvaruso G. Mule A. Ammatuna E. Di Trapani R. et al. Hepatitis Π virus reactivation and ale-mtuzumab therapy // Eur J Haematol. -2005- 74: 254−258.
- Ireland JH. O’Donnell B. Basuni AA. Kean JD. Wallace LA. Lau GK. et al. Reactivity of 13 in vitro expressed hepatitis Π surface antigen variants in 7 commercial diagnostic assays // Hepatology (Baltimore, MD). 2000- 31:11 761 182.
- Japanese Red Cross. Hepatitis. Group. R. Effect of screening for hepatitis Π‘ virus antibody and hepatitis Π virus core antibody on incidence of posttransfusion hepatitis // Lancet. 1991- 338:1040−1041.
- Jeantet D. Chemin I. Mandrand B. Tran A. Zoulim F. Merle P. et al. Cloning and expression of surface antigens from occult chronic hepatitis Π virus infections and their recognition by commercial detection assays // J Med Virol. -2004- 73:508−515.
- Jeantet D. Chemin I. Mandrand B. Zoulim F. Trepo C. Kay A. Characterization of two hepatitis Π vims populations isolated from a hepatitis Π surface antigen-negative patient//Hepatology (Baltimore, MD). 2002- 35: 1215−1224.
- Kawatani T. Suou T. Tajima F. Ishiga K. Omura H. Endo A. et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies // Eur J Haematol. 2001- 67: 4550.
- Koike K. Kobayashi M. Gondo M. Hayashi I. Osuga T. Takada S. Hepatitis Π virus DNA is frequently found in liver biopsy samples from hepatitis Π‘ virus-infected chronic hepatitis patients // J Med Virol. 1998- 54: 249−255.
- Kreutz C. Molecular, immunological and clinical properties of mutated hepatitis Π viruses // J Cell Mol Med. 2002- 6: 113−143.
- Larghi A. Leffler D. Frucht H. Rubin M. Semrad CE. Lefko-witch JH. et al. Hepatitis Π virus reactivation after kidney transplantation and new onset lymphoma // J Clin Gastroenterol. 2003- 36: 276−280.
- Larsen J. Hetland G. Skaug K. Posttransfusion hepatitis Π transmitted by blood from a hepatitis Π surface antigen-negative hepatitis Π virus carrier // Transfusion. 1990- 30: 431−432.
- Liang TJ. Baruch Y. Ben-Porath E. Enat R. Bassan L. Brown NV. et al. Hepatitis Π virus infection in patients with idiopathic liver disease // Hepatology (Baltimore, MD). 1991- 13: 1044−1051.
- Lok ASF. Liang RHS. Chiu EKW. Wong KL. Chan TK. Todd D. Reactivation of hepatitis Π virus replication in patients receiving cytotoxic therapy // Gastroenterolgy. 1991- 100: 182−188.
- Lokl Anna S. F. Et al. AASLD Practice guidelines Chronic Hepatitis B: Update 2009 // Hepatology. 2009, Vol. 50, No. 3, P. 1 — 29.
- Manzini P. Girotto M. Borsotti R. Giachino O. Guaschino R. Lanteri M. Testa D. Ghiazza P. Vacchini M. Danielle F. et al. Italian blood donors with anti-HBc and occult hepatitis Π virus infection // Haematologica.- 2007- 92(12): 16 641 670.
- Marcellin P. Giostra E. Martinot-Peignoux M. Loriot M-A. Jaegle M-L. Wolf P. et al. Redevelopment of hepatitis Π surface antigen after renal transplantation // Gastroenterology. 1991- 100: 1432−1434.i
- Marion PL In Ground squirrel hepatitis virus. In: McLachlan A, editor. Molecular biology of hepatitis Π virus. Boca Raton, Florida // CRC Press- 1991. -p. 39−51.
- Mariscal LF. Rodriguez-Inigo E. Bartolome J. Castillo I. Ortiz-Movilla N. Navacerrada C. et al. Hepatitis Π infection of the liver in chronic hepatitis Π‘ without detectable hepatitis Π virus DNA in serum // J Med Virol. 2004- 73: 177−186.
- Marusawa H. Uemoto S. Hijikata M. Ueda Y. Tanaka K. Shimotohno K. et al. Latent hepatitis Π virus infection in healthy individuals with antibodies to hepatitis Π core antigen // Hepatology (Baltimore, MD). 2000- 31: 488−495.
- Maynard M. Parvaz P. Durantel S. Chevallier M. Chevallier P. Lot M. et al. Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure // J Hepatol. 2005- 42: 279−281.
- Munoz SJ. Use of hepatitis Π core antibody-positive donors for liver transplantation//Liver Transpl. 2002- 8: 582−587.
- Nunez M. Rios P. Perez-Olmeda M. Soriano V. Lack of 'occult' hepatitis Π virus infection in HIV-infected patients// AIDS. 2002- 16: 2099−2101.
- Okuda K. Ohtsuki T. Obata H. Tomimatsu M. Okazaki N. Hasegawa H. et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients // Cancer. 1985- 56: 18−20.
- Paterlini P. Poussin K. Kew M. Franco D. Brechot C. Selective accumulation of the X transcript of hepatitis Π virus in patients negative for hepatitis Π surface antigen with hepatocellular carcinoma // Hepatology (Baltimore, MD). 1995- 21:313−321.
- Patrick Yachimski. Raymond T. Chung. Hepatitis Π Virus Infection in Liver Transplant Candidates and Recipients // Medscape General Medicine. -2005- 7(2):20.
- Penna A. Artini M. Cavalli A. Levrero M. Bertoletti A. Pilli M. et al. Long-lasting memory T-cell responses following self-limited acute hepatitis Π // J Clin Invest, 1996- 98: 1185−1194.
- Piroth L. Grappin M. Buisson M. Duong M. Portier H. Chavanet P. Hepatitis Π virus seroconversion in HIV-HBV coinfected patients treated with highly active antiretroviral therapy // J Acquir Immune Defic Syndr. 2000- 23: 356−357.
- Pollicino Π’. Squadrito G. Cerenzia G. Cacciola I. Raffa G. Crax A. et al. Hepatitis Π virus maintains its pro-oncogenic properties in the case of occult HBV infection // Gastroenterology. 2004- 126: 102−110.
- Raimondo G. Occult hepatitis Π virus infection// Jornal of Hepatology (46). -2007- 160−170.
- Raimondo G. Balsano C. Craxi A. Farinati F. Levrero M. Mondelli M. et al. Occult hepatitis Π virus infection // Dig Liver Dis. 2000- 32: 822−826.
- Ramirez S. Perez-Del-Pulgar S. Foms X. Virology and pathogenesis of hepatitis Π‘ virus recurrence // Liver Transpl. 2008- 14 Suppl 2: 527−535.
- Regan FA. Hewitt P: Barbara JA. Contreras M. Prospective investigation of transfusion transmitted infection in recipients of over 20 000 units of blood. TTI Study Group // BMJ.(Clinical research ed). 2000- 320: 403−406.
- Rehermann B. Ferrari C. Pasquinelli C. Chisari FV. The hepatitis Π virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response // Nat Med. 1996- 10:1104−1108.
- Rehermann B. Nascimbeni M. Immunology Of Hepatitis Π Virus
- And Hepatitis Π‘ Vims Infection // Nat Rev Immunol. 2005- 5(3): 215−229.
- Roche B. Samuel D. Gigou M. Feray C. Virot V. Schmets L. et al. De novo and apparent de novo hepatitis Π virus infection after liver transplantation // J Hepatol. 1997- 26: 517−526.
- Rodriguez-Luna H. Arenas J. Vargas HE. The use of virologically compromised organs in liver transplantation // Clin Liver Dis. 2003- 7(3): 573−584.i
- Sagnelli E. Pasquale G. Coppola N. Marrocco C. Scarano F. Imparato M. Sagnelli C. Scolastico C. Piccinino F. Liver histology in patients with HBsAg negative anti-HBcor and anti-HCV positive chronic hepatitis // J Med Virol. -2005 Feb- 75(2): 222.
- Saito H. Masuda T. Tada S. Ebinuma H. Yamagishi Y. Ojiro K. Inoue M. Hibi T. Hepatocellular carcinoma in Keio affiliated hospitals—diagnosis, treatment, and prognosis of this disease // Keio J Med.- 2009- 58(3): 161−175.
- Samuel D. Forns X. Berenguer M. Trautwein C. Burroughs A. Rizzetto M. et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12−14, 2006) // J Hepatol. 2006- 45: 127 143.
- Schuttler CG. Fiedler N. Schmidt K. Repp R. Gerlich WH. Schaefer S. Suppression of hepatitis Π virus enhancer 1 and 2 by hepatitis Π‘ virus core protein // J Hepatol. 2002- 37: 855−862.
- Sheu JC. Huang GT. Shih LN. Lee WQ. ChouHC. Wang JT. et al. Hepatitis Π‘ and Π viruses in hepatitis Π surface antigen-negative hepatocellular carcinoma // Gastroenterology. 1992- 103: 1322−1327.
- Shih CM. Lo SJ. Miyamura T. Chen SY. Lee YH. Suppression of hepatitis Π vims expression and replication by hepatitis Π‘ virus core protein in HuH-7 cells //J Virol. 1993- 67: 5823−5832.
- Strasser SI. McDonald GB. Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management // Blood. 1999- 93: 1127−1136.
- Su WJ. Ho MC. Ni YH. Chen HL. Hu RH. Wu YM. Chang MH. Lee PH. High-titer antibody to hepatitis Π surface antigen before liver transplantation can prevent de novo hepatitis Π infection // Pediatr Gastroenterol Nutr. 2009- 48(2): 203−208.
- Tabor E. Hoofnagle JH. Smallwood LA. Drucker JA. Pineda-Tamondong GC. Ni LY. et all Studies of donors who transmit posttransfusion hepatitis //' Transfusion.- 1979- 19: 725−731.
- Tamura S. Sugawara Y. Treatment strategy for hepatitis Π‘ after liver transplantation // J Hepatobiliary Pancreat Surg. 2008- 15(2): 111−123.
- The- Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for. hepatocellular carcinoma: a retrospective study of 435 patients // J Hepatol, 1998- 28: 751−755-
- Thiers V. Nakajima H. Kremsdorf D. Mack D. Schellekens H. Driss F. et al. Transmission of hepatitis Π from hepatitis-B-seronegative subjects // Lancet,.1 1988- 2: 1273−1276.
- Torbenson M. Thomas DL. Occult hepatitis Π // Lancet Infect Dis.- 2002- 2: 479−486.
- Vento S: Perri G. Luzzati R: Cruciani M. Garofano T. Mengoli C. et al. Clinical reactivation of hepatitis Π in anti-HBs-positive patients with AIDS // Lancet. -1989−1:332−333.
- Villa E. Grottola A. Buttafoco P. Trande P- Merighi A. Fratti N. et ah Evidence for hepatitis Π virus infection in patients with chronic hepatitis Π‘ with and without serological markers of hepatitis Π // Digest Diseases Sci- 1995- 40: 813.
- Wachs ME. Amend WJ. Ascher NL. Bretan PN. Emond J. Lake JR. et al. Therisk of transmission of hepatitis Π from HBsAg (-), HBcAb (+), HBIgM (-) organ donors//Transplantation. 1995- 59: 230−234.
- Waite J. Gilson RJC. Weller IVD. Lacey CJ. Hambling MH. Hawkins A. et al. Hepatitis Π virus reactivation or reinfection associated with HIV-1 infection // AIDS. 1988- 2: 443−448.
- Wands JR. Fujita YK. Isselbacher KJ. Degott C. Schellekens H. Datsa MC. et al. Identification and transmission of hepatitis Π virus-related variant // Proc Natl Acad Sci USA. 1986- 83: 6608−6612.
- Webster A. Brenner MK. Prentice HG. Griffiths PD. Fatal hepatitis Π reactivation after autologous bone marrow transplantation //.Bone Marrow Transplant. 1989- 4: 207−208.
- Werle-Lapostolle B. Bowden S. Locarnini S. Wursthorn K. Petersen J. Lau G. et al. Persistence of cccDNA during the natural history of chronic hepatitis Π and decline during adefovir dipivoxil therapy // Gastroenterology. 2004- 126: 1750−1758.
- Westhoff TH. Jochimsen F. Schmittel A. Stoffler-Meilicke M. Schafer JH. Zidek W. et al. Fatal hepatitis Π virus reactivation by an escape mutant following rituximab therapy // Blood. 2003- 102: 1930.
- Wursthorn K. Lutgehetmann M. Dandri M. Volz T. Buggisch P. Zollner B. et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis Π // Hepatology (Baltimore, MD). 2006- 44: 675−684.
- Yataco ML. Dickson RC. Bonatti H. Aranda-Michel J. Mendez J. Ghabril M. Dual hepatitis virus infections in liver transplant: case report and a review of theliterature // J Clin Transplant. 2009- 23(2): 282−288.
- Yoshiba M. Sekiyama K. Sugata F. Kawamoto Y. Muraoka H. Aoyama M. Post-transfusion fulminant hepatitis Π after screening for hepatitis Π virus core antibody//Lancet. 1992- 339: 253−254.
- Yotsuyanagi H. Hashidume K. Suzuki M. Maeyama S. Takay-ama T. Uchikoshi T. Role of hepatitis Π virus in hepatocarci-nogenesis in alcoholics // Alcoholism Clin Exper Res. 2004- 28: 1815−1855.
- Yu MC. Yuan JM. Ross RK. Govindarajan S. Presence of antibodies to the hepatitis Π surface antigen is associated with an excess risk for hepatocellularcarcinoma among non-Asians in Los Angeles County, California // Hepatology
- Baltimore, MD). 1997- 25: 226−228.
- Yuki N. Nagaoka T. Yamashiro M. Mochizuki K. Kaneko A. Yamamoto K. et' al. Long-term histologic and virologic outcomes of acute self-limited hepatitis Π // Hepatology (Baltimore, MD). 2003- 37: 1172−1179.
- Zoulim F. New insight on hepatitis Π virus persistence from the study of intrahepatic viral cccDNA // J Hepatol. 2005- 42: 302−308.